India Launches HPV Vaccine: A New Era for Adolescent Health

India is poised to implement the Human Papillomavirus (HPV) vaccine for adolescent girls in the upcoming weeks. This initiative signifies the culmination of India's childhood immunisation efforts and a strategic pivot towards adolescent preventive health.

The introduction of the HPV vaccine, offering protection against cervical cancer, follows a lengthy 18-year period of discussions and controversy. Initial trials between 2008-2009 in Gujarat and Andhra Pradesh faced scrutiny due to reported deaths, which were later unlinked to the vaccine, but concerns over consent procedures delayed its national adoption.

Despite scientific recommendations, India refrained from including the HPV vaccine in its national program until now. This delay meant entire cohorts missed the optimal vaccination window, contrasting with approximately 164 countries that had introduced the vaccine by January 2026.

Cervical cancer is the second most common cancer affecting Indian women, with an estimated 80,000 new cases and over 42,000 deaths annually. The vaccine, Gardasil, protects against high-risk HPV types 16 and 18, which cause the majority of these cancers.

Lessons from the prolonged introduction emphasize the need for clear communication, robust ethical standards, and consistent political commitment. Transparency and community engagement are crucial for public trust in health initiatives.

The free rollout aims to promote equity, but a comprehensive strategy including screening and treatment is vital. India is also encouraged to expand its focus to adult and elderly vaccinations, extending its preventive health architecture.